However, to our best knowledge, there have been no head-to-head trials comparing single-agent PARPi in BRCA-mutated HER2-negative advanced breast cancer [14], and only one traditional meta-analysis has compared all single-agent PARPi with treatment of physician’s choice (TPC) [15]. The gene discussed is ERBB2; the disease is breast carcinoma.